Targeting copper metabolism to defeat KRAS-driven colorectal cancer.
Institute for Research in Immunology and Cancer (IRIC), Université De Montréal, Montreal, Quebec, Canada.
KRAS-driven cancers acquire profound metabolic dependencies that are intimately linked to tumor growth. Our work revealed that colorectal cancers that harbor KRAS mutations are addicted to copper metabolism. This adaptation renders tumor cells critically dependent on the copper transporter ATP7A, which reveals copper metabolism as a promising therapeutic target for KRAS-driven colorectal cancers.
Mol Cell Oncol 2020;7(6):1822123.
Pubmed ID: 33235918